Gladstone and Merck team to bring drugs to market
13th Nov 2006, 06:59 GMT
The J. David Gladstone Institutes and drug giant Merck & Co. have struck a deal that will launch a new effort by the institutes to see its discoveries turned into commercial therapies.
Gladstone and Merck team to bring drugs to market related news:
- Merck: New pain drug safer than Vioxx — Financial news of the day - CNNMoney.com
- Merck: New drug safer than Vioxx — Business and financial news - CNNMoney.com
- Study Says Lupus Drugs May Treat Atherosclerosis — RedOrbit News - Health
- Akorn, FDC Team Up for Eye Drugs — Pharmaceuticals News from StratCenter.com
- Numerous New Targets, Increased Use of Drugs in Combination, and Premium Pricing are Contributors to the Enormous Sales Potential of Novel Cancer Therapies Entering the Market Over the Next 15 Years — Partnerships/ Joint Ventures News from StratCenter.com
- NICOX: NicOx presents preclinical results at AHA from antihypertensive collaboration with Merck & Co., Inc. — Market Wire - Medical and Healthcare
- Merck: Arcoxia heart risk same as Voltaren — United Press International - Health Business
- Merck: New pain killer safer than Vioxx — Business and financial news - CNNMoney.com
- Merck says new drug is safer than Vioxx — Cardiology News from StratCenter.com
- Tests of new Merck painkiller criticized — baltimoresun.com - health & science
Latest news from bizjournals.com Health Care:Pharmaceuticals headlines:
- United BioSource makes 10th buy, looks for more
- Nonprofits starting to invest in drug companies
- Accentia making changes to its business formula, market focus
- GSK terminates agreement for Genaera frog product
- Abbott expects to double vascular business sales
- Mayo to shut down drug-testing unit
- MIT, Dana-Farber win major cancer grants
- Service Bancorp chair resigns
- Introgen strikes nanotech deal with M.D. Anderson
- Joslin spins out first-ever company, Veraxa Health Inc.